Market Place
Sourcing Support
Appili Reports Q2 FY 2025 Financial & Operational Results
14 Nov 2024 //
GLOBENEWSWIRE
Aditxt’s Target Acquisition Appili Announces Meeting Results
07 Nov 2024 //
BUSINESSWIRE
Appili Therapeutics Announces Special Meeting Results
06 Nov 2024 //
GLOBENEWSWIRE
Appili Therapeutics Aligns with FDA on ATI-1801 NDA
31 Oct 2024 //
GLOBENEWSWIRE
Appili Provides Update On ATI-1701 Vaccine Candidate At IDWeek™
17 Oct 2024 //
GLOBENEWSWIRE
Appili Shareholders Vote On Aditxt Acquisition November 6 2024
10 Oct 2024 //
BUSINESSWIRE
Appili Mails Circular For Special Shareholder Meeting
10 Oct 2024 //
GLOBENEWSWIRE
Appili Therapeutics – Press Release Correction
10 Oct 2024 //
GLOBENEWSWIRE
Appili Therapeutics Announces Annual Meeting Results
17 Sep 2024 //
GLOBENEWSWIRE
Appili Therapeutics Amends Arrangement With Aditxt
21 Aug 2024 //
GLOBENEWSWIRE
Aditxt Amends Arrangement Agreement With Appili Therapeutics
21 Aug 2024 //
BUSINESSWIRE
Appili Therapeutics Reports Q1 2025 Financial And Operational Results
13 Aug 2024 //
GLOBENEWSWIRE
Aditxt Amends Appili Therapeutics Deal, Targets September 30 Closing
25 Jul 2024 //
BUSINESSWIRE
Appili Therapeutics Announces Second Amendment to Arrangement Agreement
18 Jul 2024 //
GLOBENEWSWIRE
Appili Therapeutics Amends Arrangement Agreement And Increases Bridge Loan
02 Jul 2024 //
GLOBENEWSWIRE
Appili Therapeutics Reports Fiscal Year 2024 Financial and Operational Results
25 Jun 2024 //
GLOBENEWSWIRE
Appili Therapeutics Announces Additional Bridge Loan from Bloom Burton & Co.
26 Apr 2024 //
GLOBENEWSWIRE
Aditxt Signs a Definitive Agreement to Acquire Appili Therapeutics Inc
02 Apr 2024 //
BUSINESSWIRE
Appili Therapeutics Signs Definitive Agreement to be Acquired by Aditxt, Inc.
02 Apr 2024 //
GLOBENEWSWIRE
Researchers Publish Manuscript on the Prevention Response to Tularemia Outbreaks
12 Mar 2024 //
GLOBENEWSWIRE
Appili Reports Financial Results for Third Quarter of Fiscal Year 2024
13 Feb 2024 //
GLOBENEWSWIRE
Appili Announces Issuance of Patent for ATI-1701 Biodefense Vaccine Candidate
15 Dec 2023 //
BUSINESSWIRE
Appili Reports Financial Results for Second Quarter of Fiscal Year 2024
13 Nov 2023 //
BUSINESSWIRE
Appili’s Biodefense Vaccine Candidate ATI-1701 is Awarded Additional Funding
25 Oct 2023 //
BUSINESSWIRE
Appili Therapeutics Presents at the 10th International Tularemia Conference
27 Sep 2023 //
BUSINESSWIRE
Appili Therapeutics Announces Results of Annual Meeting of Shareholders
27 Sep 2023 //
BUSINESSWIRE
Canada`s Appili gets US FDA approval for oral antibiotic solution
26 Sep 2023 //
REUTERS
Appili Therapeutics Reports Financial Results for Q1 of Fiscal Year 2024
11 Aug 2023 //
BUSINESSWIRE
Appili Therapeutics – Press Release Correction
23 Jun 2023 //
BUSINESSWIRE
Appili Therapeutics Announces Issuance of Patent for ATI-1501 Liquid Oral
24 May 2023 //
BUSINESSWIRE
EverGlade Consulting Assists Appili in Successful Pursuit of DTRA Funding
11 May 2023 //
PR NEWSWIRE
Appili Secures Contract for ATI-1701 Funding from the U.S. Air Force Academy
08 May 2023 //
BUSINESSWIRE
Appili to Present at the 2023 Bloom Burton & Co. Healthcare Investor Conference
18 Apr 2023 //
BUSINESSWIRE
Appili Therapeutics Appoints Dr. Gary Nabors as Chief Development Officer
03 Apr 2023 //
BUSINESSWIRE
Appili Therapeutics Announces Additional Funding of CAD$2.5 million
20 Mar 2023 //
BUSINESSWIRE
Appili Reports Financial and Operational Results for Q3 of Fiscal Year 2023
14 Feb 2023 //
BUSINESSWIRE
Appili Therapeutics Announces that FDA accepts the ATI-1501 NDA
08 Feb 2023 //
BUSINESSWIRE
Biotech receives award from DOD; Regulators accept Appili Therapeutics` NDA
08 Feb 2023 //
ENDPTS
Appili Appoints Dr. Carl Gelhaus & Arthur Baran to support the ATI-1701 Program
17 Jan 2023 //
BUSINESSWIRE
Appili Announces Notice of Allowance from U.S. Patent Office for ATI-1501
13 Jan 2023 //
BUSINESSWIRE
Appili ATI-1701 Biodefense Vaccine Secures $14M of Funding from U.S. Department
14 Nov 2022 //
BUSINESSWIRE
Appili Therapeutics Reports Financial and Results for 2Q of Fiscal Year 2023
10 Nov 2022 //
BUSINESSWIRE
Appili Therapeutics Provides Update Ph3 PRESECO Clinical Trial Evaluating Avigan
14 Oct 2022 //
APPILITHERAPEUTICS
Appili Therapeutics Announces Results of Annual Meeting of Shareholders
22 Sep 2022 //
BUSINESSWIRE
Appili Therapeutics Reports Financial and Operational Results for1Qof FY2023
12 Aug 2022 //
BUSINESSWIRE
Appili Therapeutics to Present at WorldLeish7 Conference in Cartagena, Columbia
02 Aug 2022 //
BUSINESSWIRE
Appili Therapeutics Reports Fiscal Year 2022 Financial and Operational Results
29 Jun 2022 //
BUSINESSWIRE
Appili Therapeutics Announces Closing of Public Offering of $4,500,000
26 May 2022 //
BUSINESSWIRE
Appili Therapeutics Announces Pricing of Overnight Marketed Equity Offering
18 May 2022 //
BUSINESSWIRE
Appili Therapeutics Announces Overnight Marketed Equity Offering
17 May 2022 //
BUSINESSWIRE
Appili Therapeutics to Present at the 2022 Bloom Burton & Co. Conference
27 Apr 2022 //
BUSINESSWIRE
Appili Announces New Late-Stage Clinical Program ATI-1801 for Leishmaniasis
13 Apr 2022 //
BUSINESSWIRE
Appili Therapeutics Announces Non-Convertible Secured Loan of US$3.6M
29 Mar 2022 //
BUSINESSWIRE
Appili Tx Announces Over US$10M in New Funding for ATI-1701
28 Feb 2022 //
BUSINESSWIRE
Appili Therapeutics Reports Financial and Operational Results for Q3 FY 2022
14 Feb 2022 //
BUSINESSWIRE
Appili Tx Expands ATI-1501 Commercial Agreement with Saptalis Pharmaceuticals
08 Feb 2022 //
BUSINESSWIRE
Appili Therapeutics Announces Update to Funding Agreement With The Lind Partners
22 Dec 2021 //
BUSINESSWIRE
Appili: Positive 1Y Challenge Results from Preclinical Study of ATI-1701
19 Nov 2021 //
BUSINESSWIRE
AiPharma and Appili Therapeutics form strategic alliance
05 Oct 2021 //
PHARMAFIELD
Appili and AiPharma to advance Avigan/Reeqonus development
30 Sep 2021 //
PHARMACEUTICAL-TECHNOLOGY
